PROTAC mHTT Degrader-1

PROTAC mHTT Degrader-1 是一种可穿透血脑屏障的突变亨廷顿蛋白 (mHTT) PROTAC 降解剂,能特异性识别致病性 mHTT 聚集体并招募 Cereblon (CRBN),从而诱导 mHTT 泛素化并经蛋白酶体降解,进而减轻 mHTT 诱导的细胞毒性和神经炎症,在 R6/2 亨廷顿舞蹈病小鼠模型中降低脑内蛋白聚集水平并改善动物体重、运动协调性及存活率,可用于亨廷顿病及其他神经退行性疾病的 PROTAC 疗法研究(粉色:Huntingtin 配体 (MS-V46579);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-X89683))。
产品编号: MS-Y32203 CAS No.: 2919475-43-5 分子式: C33H35N5O7 分子量: 613.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

PROTAC mHTT Degrader-1 是一种可穿透血脑屏障的突变亨廷顿蛋白 (mHTT) PROTAC 降解剂,能特异性识别致病性 mHTT 聚集体并招募 Cereblon (CRBN),从而诱导 mHTT 泛素化并经蛋白酶体降解,进而减轻 mHTT 诱导的细胞毒性和神经炎症,在 R6/2 亨廷顿舞蹈病小鼠模型中降低脑内蛋白聚集水平并改善动物体重、运动协调性及存活率,可用于亨廷顿病及其他神经退行性疾病的 PROTAC 疗法研究(粉色:Huntingtin 配体 (MS-V46579);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-X89683))。

生物实验数据

生物活性 PROTAC mHTT Degrader-1 is a blood-brain barrier-penetrant mutant huntingtin (mHTT) PROTAC degrader that specifically recognizes pathogenic mHTT aggregates and recruits Cereblon (CRBN) to induce mHTT ubiquitination and proteasomal degradation, thereby alleviating mHTT-induced cytotoxicity and neuroinflammation and, in the R6/2 Huntington's disease mouse model, reducing brain protein aggregation levels and improving body weight, motor coordination, and survival rate, and can be used for research on PROTAC therapies for Huntington's disease and other neurodegenerative diseases (pink: Huntingtin ligand (MS-V46579); blue: Cereblon ligand (MS-V29738); black: linker (MS-X89683)).
IC50 & Target

Cereblon

 

体外研究
(In Vitro)

PROTAC mHTT Degrader-1 (PROTAC 2′) (1 μM;22 h) 可显著降低表达 HTT (Q)109-eYFP 的 N2a 细胞中 mHTT 聚集体阳性细胞比例与不溶性 mHTT 聚集体水平,对可溶性 mHTT 水平无显著影响;可降低细胞内 DNA 损伤标志物 p-H2A.X (Ser139) 的水平,抑制 mHTT 诱导的细胞凋亡通路激活。
PROTAC mHTT Degrader-1 (PROTAC 2′) (1 μM;22 h) 可减少细胞内 mHTT 寡聚体比例,实现对可溶性寡聚体和不溶性聚集体的同步靶向降解;其降解作用可被蛋白酶体抑制剂 MG132 显著逆转,证实其通过泛素 - 蛋白酶体系统发挥作用。
PROTAC 2′ (0.01-10 μM;22 h) 可剂量依赖性地选择性降解表达 HTT (Q)109-eYFP 的 N2a 细胞中的 mHTT 聚集体,对非致病性的 HTT (Q)25-eYFP 水平无明显影响。
PROTAC 2′ (1 μM;48 h) 可显著提升表达 HTT (Q)109-eYFP 的 N2a 细胞的活力,有效缓解 mHTT 诱导的神经细胞毒性。

Cell Viability Assay

Cell Line: Mouse neuroblastoma N2a cells transfected with HTT(Q)109-eYFP or HTT(Q)25-eYFP plasmid
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM
Incubation Time: 22 h
Result: Degraded insoluble HTT(Q)109-eYFP aggregates in a dose-dependent manner, while it exerted negligible effect on the level of soluble HTT(Q)109-eYFP and nonpathogenic HTT(Q)25-eYFP across all tested concentrations.
Reduced the level of DNA damage marker phosphor-H2A.X (Ser139) at 1 μM, and relieved the mHTT-induced cellular apoptosis pathway activation.
体内研究
(In Vivo)

PROTAC mHTT Degrader-1 (PROTAC 2′) (3 mg/kg;皮下注射;单次;给药后观察 6 h) 野生型 B6CBA 小鼠模型,可穿透血脑屏障,在给药后 6 h 内可在小鼠脑组织中持续检测到,平均浓度维持在约 1.96 ppb。
PROTAC mHTT Degrader-1 (3 mg/kg/ 周;皮下注射;每周 1 次;连续给药 5 周) 在野生型 B6CBA 小鼠模型中,长期给药后小鼠体重、大脑皮层厚度、纹状体体积与对照组无显著差异,血清肝肾功能指标无异常,无明显肝、肾、脑组织毒性。
PROTAC mHTT Degrader-1 (3 mg/kg/ 周;皮下植入渗透泵持续给药;持续输注;给药 4 周) 在 B6CBA-R6/2 亨廷顿病小鼠模型中,可显著延缓模型小鼠体重下降,改善运动协调能力与自发探索行为,延长生存期;同时可降低小鼠脑内 mHTT 聚集体水平与神经炎症,缓解皮层与纹状体萎缩,部分恢复神经元功能。

Animal Model: Wild-type (WT) B6CBA mice, 6 weeks of age at administration, n=9 per time point
Dosage: 3 mg/kg/week
Administration: subcutaneous (SC) injection once a week for 5 consecutive weeks
Result: No structural abnormalities were observed in the cortical thickness, striatal volume of the brain, or the morphology of liver and kidney tissues in PROTAC 2′-treated mice.
There were no significant differences in serum levels of liver function markers (AST, ALT) and kidney function markers (BUN, CRE), indicating no evident hepatotoxicity or nephrotoxicity of the compound after long-term low-dose administration.
Animal Model: B6CBA-Tg(HDexon1)62Gpb/1J (R6/2) transgenic Huntington’s disease mice and wild-type B6CBA mice, 6 weeks of age at the start of administration
Dosage: 3 mg/kg/week
Administration: subcutaneously implanted osmotic pumps for 4 weeks
Result: Markedly delayed the progressive weight loss of R6/2 mice, and maintained higher body weight of the model animals until 11 weeks of age.
Significantly improved the motor coordination of R6/2 mice in the rotarod assay from 10 to 13 weeks of age, and increased the rearing frequency of the model mice in the cylinder assay at 14 weeks of age.
Significantly extended the survival of R6/2 mice: 50% of treated mice survived to 16 weeks and 35% survived to 17 weeks, while all vehicle-treated R6/2 mice died by 15 weeks of age.

化学信息

分子量 613.66
分子式 C33H35N5O7
CAS No. 2919475-43-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础